Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
71 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Show Display Options
RSS Create an RSS feed from your search for:
gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Condition: Breast Cancer
Intervention: Drug: Pegylated liposomal doxorubicin
2 Recruiting A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: Denosumab
3 Recruiting Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer
Conditions: Primary Breast Cancer ER+ve;   Primary Breast Cancer AR+ve TNBN
Interventions: Drug: Enzalutamide;   Drug: Exemestane
4 Recruiting Pre-operative Zoledronate in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Zoledronate
5 Not yet recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC).
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
6 Recruiting Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate;   Drug: Placebo;   Procedure: Digital mammography;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration;   Procedure: Fine needle aspiration;   Other: Quality of Life Assessment
7 Recruiting DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Digoxin
8 Recruiting TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: TDM1;   Drug: Lapatinib;   Drug: Abraxane
9 Recruiting CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Conditions: Metastatic Breast Adenocarcinoma;   Breast Cancer
Intervention: Drug: CR1447
10 Not yet recruiting Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Conditions: Breast Cancer Female NOS;   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer;   Tubular Breast Cancer Stage III
Interventions: Drug: Denosumab;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab
11 Recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
12 Recruiting A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Epirubicin+Cyclophosphamide;   Drug: liposomal-doxorubicin+Cyclophosphamide
13 Unknown  Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride
14 Recruiting 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
15 Not yet recruiting Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
Condition: Breast Cancer
Intervention: Drug: Capecitabine
16 Not yet recruiting Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
Conditions: Estrogen Receptor Positive;   Postmenopausal;   Stage 0 Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer
Interventions: Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery
17 Recruiting FDHT PET and Bicalutamide in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Bicalutamide;   Procedure: FDHT PET
18 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel;   Drug: Pertuzumab
19 Recruiting A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Conditions: Head and Neck Neoplasms;   Lung Neoplasms;   Urinary Bladder Neoplasms;   Breast Neoplasms
Interventions: Drug: 5-Fluoro-2-Deoxycytidine (FdCyd);   Drug: Tetrahydrouridine (THU)
20 Recruiting Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years